ES2169060T3 - Agentes citotoxicos de longitud de onda especifica. - Google Patents
Agentes citotoxicos de longitud de onda especifica.Info
- Publication number
- ES2169060T3 ES2169060T3 ES94115192T ES94115192T ES2169060T3 ES 2169060 T3 ES2169060 T3 ES 2169060T3 ES 94115192 T ES94115192 T ES 94115192T ES 94115192 T ES94115192 T ES 94115192T ES 2169060 T3 ES2169060 T3 ES 2169060T3
- Authority
- ES
- Spain
- Prior art keywords
- tissues
- specific
- cells
- wave length
- cytotoxic agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 150000004032 porphyrins Chemical class 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 229940043517 specific immunoglobulins Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
UN GRUPO DE HIDRO-MONOBENZOPORFIRINAS "PORFIRINAS VERDES" (GP) QUE TIENEN UNA ABSORCION MAXIMA DEL ORDEN DE 670 NOMETROS ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES O CONDICIONES QUE ESTEN SUJETAS A TRATAMIENTO CON UN DERIVADO DE HEMATOPORFIRINA (HPD) EN PRESENCIA DE LUZ, O PARA TRATAR VIRUS, CELULAS Y TEJIDOS GENERALMENTE PARA DESTRUIR OBJETIVOS INDESEADOS. EL USO DE GP DE LA INVENCION PERMITE QUE LA IRRADICION USE LONGITUDES DE ONDA DIFERENTES DE AQUELLAS ABSORBIDAS POR LA SANGRE. EL GP DE LA INVENCION PUEDE TAMBIEN SER CONJUGADO CON LIGANTES ESPECIFICOS PARA EL RECEPTOR O INMOGLOBULINAS ESPECIFICAS O FRAGMENTOS CONSIGUIENTES PARA ENCUADRAR TEJIDOS ESPECIFICOS O CELULAS PARA EL TRATAMIENTO POR RADIACION. EL USO DE ESTOS MATERIALES PERMITE QUE SE USEN NIVELES INFERIORES DE MEDICAMENTO, EVITANDO ASI REACCIONES SECUNDARIAS QUE PUEDAN DESTRUIR TEJIDOS NORMALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/221,161 US4920143A (en) | 1987-04-23 | 1988-07-19 | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2169060T3 true ES2169060T3 (es) | 2002-07-01 |
Family
ID=22826617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES89307281T Expired - Lifetime ES2080745T3 (es) | 1988-07-19 | 1989-07-19 | Agentes citotoxicos de longitud de onda especifica |
ES94115192T Expired - Lifetime ES2169060T3 (es) | 1988-07-19 | 1989-07-19 | Agentes citotoxicos de longitud de onda especifica. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES89307281T Expired - Lifetime ES2080745T3 (es) | 1988-07-19 | 1989-07-19 | Agentes citotoxicos de longitud de onda especifica |
Country Status (10)
Country | Link |
---|---|
US (1) | US4920143A (es) |
EP (2) | EP0641796B1 (es) |
AT (2) | ATE209650T1 (es) |
AU (1) | AU638675B2 (es) |
CA (1) | CA1339927C (es) |
DE (3) | DE68924215T2 (es) |
ES (2) | ES2080745T3 (es) |
GR (1) | GR3017426T3 (es) |
LU (1) | LU90718I2 (es) |
NL (1) | NL300037I2 (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
USRE38994E1 (en) | 1988-07-20 | 2006-02-28 | Health Research, Inc. | Pyropheophorbides conjugates and their use in photodynamic therapy |
USRE39094E1 (en) * | 1988-07-20 | 2006-05-09 | Health Research, Inc. | Pyropheophorbides and their use in photodynamic therapy |
US5198460A (en) * | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
EP0476011A1 (en) * | 1989-06-07 | 1992-03-25 | The University Of British Columbia | Photosensitizing diels-alder porphyrin derivatives |
US5087636A (en) * | 1990-02-20 | 1992-02-11 | University Of British Columbia | Method to destroy malignant cells in mononuclear cell populations |
US5214036A (en) * | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
US5053423A (en) * | 1990-03-22 | 1991-10-01 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
US5120649A (en) * | 1990-05-15 | 1992-06-09 | New York Blood Center, Inc. | Photodynamic inactivation of viruses in blood cell-containing compositions |
GB9014307D0 (en) * | 1990-06-27 | 1990-08-15 | Scient Generics Ltd | Method of treatment and compositions therefor |
US5219878A (en) * | 1990-10-05 | 1993-06-15 | Queen's University | Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents |
US5435307A (en) * | 1991-03-29 | 1995-07-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Surface fluorescent monitor |
CA2087902C (en) * | 1992-02-05 | 2006-10-17 | Narendra Raghunathji Desai | Liposome compositions of porphyrin photosensitizers |
US6890555B1 (en) * | 1992-02-05 | 2005-05-10 | Qlt, Inc. | Liposome compositions of porphyrin photosensitizers |
US5330741A (en) * | 1992-02-24 | 1994-07-19 | The Regents Of The University Of California | Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors |
CA2097280A1 (en) * | 1992-06-01 | 1993-12-02 | Sandor G. Vari | Apparatus and method of use for a photosensitizer enhanced fluorescence based bipsy needle |
CA2142711A1 (en) * | 1992-08-17 | 1994-03-03 | Anna M. Richter | Method for destroying or inhibiting growth of unwanted cells or tissues |
US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
ITFI940095A1 (it) * | 1994-05-23 | 1995-11-23 | Molteni & C | Coniugati fotodinamici aventi proprieta' biocide |
US5882328A (en) * | 1995-01-13 | 1999-03-16 | Qlt Phototherapeutics, Inc. | Method to prevent transplant rejection |
US5789433A (en) * | 1995-01-17 | 1998-08-04 | Quadra Logic Technologies, Inc. | Green porphyrins as immunomodulators |
US6107325A (en) * | 1995-01-17 | 2000-08-22 | Qlt Phototherapeutics, Inc. | Green porphyrins as immunomodulators |
US6096776A (en) * | 1995-01-17 | 2000-08-01 | Qlt Phototherapeutics, Inc. | Green porphyrins as immunomodulators |
DE19514088A1 (de) | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen |
US5707608A (en) * | 1995-08-02 | 1998-01-13 | Qlt Phototherapeutics, Inc. | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
WO1997026885A1 (en) * | 1996-01-23 | 1997-07-31 | The General Hospital Corporation Doing Business As Massachusetts General Hospital | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors |
WO1999013943A1 (en) | 1996-03-05 | 1999-03-25 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
US5693789A (en) * | 1996-04-10 | 1997-12-02 | Abbott Laboratories | Process for the preparation of a protoporphyrin |
US5834503A (en) | 1996-06-14 | 1998-11-10 | Qlt Phototherapeutics, Inc. | Methods to treat arterial plaque |
US6043237A (en) * | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
US6756396B1 (en) * | 1997-05-07 | 2004-06-29 | Qlt Inc. | Ethylene glycol esters as photoactive agents |
US5880145A (en) * | 1997-05-07 | 1999-03-09 | The University Of British Columbia | Class of benzoporphyrin derivative photoactive compounds |
DK0983272T3 (da) * | 1997-05-07 | 2004-03-01 | Univ British Columbia | En ny klasse af fotoaktive forbindelser, der består af benzoporphyrinderivater |
HU221754B1 (hu) * | 1997-05-07 | 2002-12-28 | Qlt Inc | Fotoaktív szerekként alkalmazható monohidrobenzoporfirin származékok etilénglikol észterei |
WO1999004857A1 (de) | 1997-07-28 | 1999-02-04 | Novartis Ag | Vorrichtung und verfahren zum bestrahlen eines auges eines patienten für eine photodynamische therapie |
CA2221912A1 (en) * | 1997-11-21 | 1999-05-21 | David Dolphin | Photosensitizers with improved biodistribution and light-absorbing properties |
US6316215B1 (en) | 1999-12-27 | 2001-11-13 | Edwin L. Adair | Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods |
EP1045704B1 (en) | 1998-01-06 | 2004-09-22 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
WO2000061584A1 (en) | 1999-04-14 | 2000-10-19 | The University Of British Columbia | IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS |
US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
US7122568B1 (en) | 1999-11-17 | 2006-10-17 | Qlt, Inc. | Use of low-dose PDT to inhibit restenosis |
US6190877B1 (en) | 1999-12-27 | 2001-02-20 | Edwin L. Adair | Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques |
US6750037B2 (en) * | 1999-12-27 | 2004-06-15 | Edwin L. Adair | Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques |
US6984498B2 (en) * | 1999-12-27 | 2006-01-10 | Adair Edwin L | Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques |
BR0109499A (pt) * | 2000-03-24 | 2002-12-10 | Novartis Ag | Tratamento melhorado de neovascularização |
WO2001085213A2 (en) | 2000-05-08 | 2001-11-15 | The University Of British Columbia | Supports for photosensitizer formulations |
US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
US20030103995A1 (en) | 2001-06-04 | 2003-06-05 | Hamblin Michael R. | Detection and therapy of vulnerable plaque with photodynamic compounds |
ES2306785T3 (es) * | 2001-11-02 | 2008-11-16 | The Governors Of The University Of Alberta | Composiciones de micelas que contienen fosfolipidos pegilados y un fotosensibilizador. |
AU2002340659B2 (en) * | 2001-11-09 | 2008-04-10 | Qlt Inc. | Photodynamic therapy for the treatment of hair loss |
EP1374912B1 (en) * | 2002-06-21 | 2006-08-16 | Edwin L. Adair | Use of metaloporphyrins for treatment of arteriosclerotic lesions |
US20060258629A1 (en) * | 2002-10-18 | 2006-11-16 | Freeman William R | Photodynamic therapy for ocular neovascularization |
US20040220167A1 (en) * | 2003-05-02 | 2004-11-04 | Nasrollah Samiy | Methods of treating neuralgic pain |
CA2437638A1 (en) * | 2003-08-20 | 2005-02-20 | John Robert North | Photodynamic therapy |
CA2457214A1 (en) | 2004-02-06 | 2005-08-06 | Qlt Inc. | Photodynamic therapy for the treatment of acne |
US20060052286A1 (en) * | 2004-08-13 | 2006-03-09 | Yale University | Factor VII conjugates for selectively treating neovascularization disorders |
US7655392B2 (en) | 2004-10-29 | 2010-02-02 | Cerus Corporation | Quenching methods for red blood cell inactivation process |
ES2636563T3 (es) | 2008-04-09 | 2017-10-06 | Cerus Corporation | Método de reducción de la deshidratación en una composición de glóbulos rojos |
US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
EP2663285A2 (en) | 2011-01-13 | 2013-11-20 | Qlt Inc. | Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof |
AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
CN104703624A (zh) | 2012-07-11 | 2015-06-10 | 德米拉股份有限公司 | 局部递送光敏剂的药物组合物及其应用 |
MX2016003256A (es) | 2013-09-12 | 2016-06-07 | Halozyme Inc | Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos. |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
AU2018235945A1 (en) | 2017-03-14 | 2019-10-17 | Ohio State Innovation Foundation | Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates |
WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2951800A (en) * | 1957-11-13 | 1960-09-06 | Monsanto Chemicals | Photoxidation processes utilizing improved catalysts |
US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
DE3381616D1 (de) * | 1982-09-27 | 1990-07-05 | Photofrin Medical Inc | Gereinigte hemaf 3381400inabkoemmlinge fuer diagnose und tumorbehandlung sowie verfahren. |
US4675338A (en) * | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
AU583854B2 (en) * | 1984-09-13 | 1989-05-11 | Cytogen Corporation | Antibody therapeutic agent conjugates |
US4883790A (en) * | 1987-01-20 | 1989-11-28 | University Of British Columbia | Wavelength-specific cytotoxic agents |
-
1988
- 1988-07-19 US US07/221,161 patent/US4920143A/en not_active Expired - Lifetime
-
1989
- 1989-07-17 CA CA000605858A patent/CA1339927C/en not_active Expired - Lifetime
- 1989-07-19 AT AT94115192T patent/ATE209650T1/de not_active IP Right Cessation
- 1989-07-19 ES ES89307281T patent/ES2080745T3/es not_active Expired - Lifetime
- 1989-07-19 EP EP94115192A patent/EP0641796B1/en not_active Expired - Lifetime
- 1989-07-19 AU AU38258/89A patent/AU638675B2/en not_active Expired
- 1989-07-19 AT AT89307281T patent/ATE127696T1/de active
- 1989-07-19 ES ES94115192T patent/ES2169060T3/es not_active Expired - Lifetime
- 1989-07-19 DE DE68924215T patent/DE68924215T2/de not_active Expired - Lifetime
- 1989-07-19 DE DE68929351T patent/DE68929351T2/de not_active Expired - Lifetime
- 1989-07-19 EP EP89307281A patent/EP0352076B1/en not_active Expired - Lifetime
- 1989-07-19 DE DE2001199008 patent/DE10199008I2/de active Active
-
1995
- 1995-09-18 GR GR950402549T patent/GR3017426T3/el unknown
-
2000
- 2000-01-17 LU LU90718C patent/LU90718I2/fr unknown
-
2001
- 2001-01-15 NL NL300037C patent/NL300037I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
DE68924215D1 (de) | 1995-10-19 |
EP0352076A3 (en) | 1991-07-17 |
ATE127696T1 (de) | 1995-09-15 |
ATE209650T1 (de) | 2001-12-15 |
GR3017426T3 (en) | 1995-12-31 |
EP0352076B1 (en) | 1995-09-13 |
DE68929351D1 (de) | 2002-01-10 |
NL300037I1 (nl) | 2001-03-01 |
DE68929351T2 (de) | 2002-05-08 |
DE68924215T2 (de) | 1996-02-15 |
NL300037I2 (nl) | 2001-08-01 |
AU638675B2 (en) | 1993-07-08 |
EP0641796B1 (en) | 2001-11-28 |
AU3825889A (en) | 1990-02-08 |
EP0641796A1 (en) | 1995-03-08 |
DE10199008I2 (de) | 2004-10-14 |
ES2080745T3 (es) | 1996-02-16 |
US4920143A (en) | 1990-04-24 |
CA1339927C (en) | 1998-06-23 |
DE10199008I1 (de) | 2003-06-12 |
EP0352076A2 (en) | 1990-01-24 |
LU90718I2 (fr) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2169060T3 (es) | Agentes citotoxicos de longitud de onda especifica. | |
Fingar et al. | Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response | |
US5913884A (en) | Inhibition of fibrosis by photodynamic therapy | |
EP0947222B1 (en) | Method of activating photosensitive agents | |
US20050004510A1 (en) | Noninvasive vascular therapy | |
ES2055735T3 (es) | Agentes citotoxicos con longitud de onda especifica. | |
JP2002522110A (ja) | 光エネルギを用いた色素沈着組織の治療方法 | |
KR20010083045A (ko) | 치료제의 다광자 광활성화를 위한 개선된 방법 및 장치 | |
EP0425566A4 (en) | New photosensitizing agents | |
Wachter et al. | Simultaneous two-photon excitation of photodynamic therapy agents | |
Biolo et al. | Photodynamic therapy of B16 pigmented melanoma with liposome‐delivered Si (IV)‐naphthalocyanine | |
EP1120119A4 (en) | REMEDIES FOR PHOTOCHEMOTHERAPY | |
WO2000041725A3 (en) | Therapeutic compositions for metabolic bone disorders or bone metastases | |
WO1992000106A3 (en) | Method of treatment and compositions therefore | |
PT1267931E (pt) | Derivados de rodamina para o diagnostico e tratamento fotodinamicos | |
McKenzie | How may external and interstitial illumination be compared in laser photodynamic therapy? | |
EP1569630A1 (en) | Methods for preventing phototoxic damage during photodynamic therapy | |
RU2146159C1 (ru) | Способ фотодинамической терапии злокачественных новообразований | |
US6586419B1 (en) | Phototherapeutic inactivation of ocular viruses | |
AU757565B2 (en) | A device for protection against the sun and application of substance to the skin | |
Nyamekye | Vascular and other non-tumour applications of photodynamic therapy | |
RU96107054A (ru) | Способ фотодинамической терапии злокачественных новообразований | |
RU2229906C2 (ru) | Способ волновой терапии | |
ES2022327B3 (es) | Camara de irradiacion para sistema de tratamiento de pacientes por fotoactivacion | |
RU2113254C1 (ru) | Способ лечения злокачественных опухолей методом фотодинамической терапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 641796 Country of ref document: ES |